William Blair Investment Management LLC Makes New $26.91 Million Investment in Palvella Therapeutics, Inc. $PVLA

William Blair Investment Management LLC bought a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 195,070 shares of the company’s stock, valued at approximately $26,906,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Palvella Therapeutics by 114.3% in the third quarter. Russell Investments Group Ltd. now owns 47,892 shares of the company’s stock valued at $6,606,000 after purchasing an additional 25,547 shares in the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in shares of Palvella Therapeutics during the third quarter worth about $7,259,000. Keybank National Association OH grew its holdings in shares of Palvella Therapeutics by 30.7% during the third quarter. Keybank National Association OH now owns 3,898 shares of the company’s stock worth $538,000 after buying an additional 915 shares in the last quarter. Ethic Inc. bought a new position in shares of Palvella Therapeutics during the third quarter worth about $308,000. Finally, Alps Advisors Inc. grew its holdings in shares of Palvella Therapeutics by 33.0% during the third quarter. Alps Advisors Inc. now owns 19,099 shares of the company’s stock worth $2,634,000 after buying an additional 4,743 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,313 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $124.58, for a total value of $537,313.54. Following the completion of the transaction, the chief operating officer directly owned 2,165 shares in the company, valued at $269,715.70. This trade represents a 66.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George Jenkins sold 13,352 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $151.96, for a total value of $2,028,969.92. Following the completion of the transaction, the director owned 161,893 shares of the company’s stock, valued at approximately $24,601,260.28. This represents a 7.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 67,306 shares of company stock valued at $9,800,571. 17.20% of the stock is currently owned by company insiders.

Palvella Therapeutics Trading Down 0.5%

Shares of Palvella Therapeutics stock traded down $0.70 during trading hours on Friday, reaching $152.48. 240,297 shares of the company’s stock were exchanged, compared to its average volume of 281,191. The stock has a market cap of $2.23 billion, a P/E ratio of -27.72 and a beta of -0.21. The company has a 50 day moving average of $143.56 and a two-hundred day moving average of $129.97. Palvella Therapeutics, Inc. has a fifty-two week low of $72.22 and a fifty-two week high of $179.95.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.08. As a group, analysts expect that Palvella Therapeutics, Inc. will post -6.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PVLA shares. HC Wainwright initiated coverage on Palvella Therapeutics in a research note on Friday, November 6th. They issued a “strong-buy” rating on the stock. Raymond James Financial set a $226.00 price target on shares of Palvella Therapeutics in a research note on Friday, October 16th. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Oppenheimer lifted their price objective on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the company an “outperform” rating in a report on Friday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $213.85.

Check Out Our Latest Analysis on PVLA

Palvella Therapeutics Profile

(Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Read More

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report).

Institutional Ownership by Quarter for Palvella Therapeutics (NASDAQ:PVLA)

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.